The societal impact of inclisiran in England: Evidence from a population health approach.

AIM: As first-in-class cholesterol-lowering small interfering ribonucleic acid (siRNA), inclisiran provides effective reductions in low-density lipoprotein cholesterol (LDL-C) to achieve better cardiovascular (CV) health. We estimate health and socioeconomic effects, of introducing inclisiran according to a population health agreement in England.

DATA & METHODS: Building on the inclisiran cost-effectiveness model, a Markov model simulates health gains in terms of avoided CV events and CV deaths due to add-on inclisiran treatment for patients aged 50 years and older with pre-existing Atherosclerotic Cardiovascular Disease (ASCVD). These are translated into socioeconomic effects, defined as societal impact (SI). Therefore, we quantify avoided productivity losses in terms of paid and unpaid work productivity and monetize them according to gross value added (GVA). Furthermore, we calculate value chain effects for paid work activities, drawing on value-added multipliers based on input-output tables. The derived value-invest ratio (VIR) compares avoided productivity losses against the increased healthcare costs.

RESULTS: Our results show that 138,647 CV events could be avoided over a period of ten years. The resulting SI amounts to £8.17bn, whereas additional healthcare costs are estimated at £7.94bn. This translates into a VIR of 1.03.

CONCLUSION: Our estimates demonstrate the potential health and socioeconomic value of inclisiran. Thereby, we highlight the importance to treat CVD and illustrate the impact a large-scale intervention can have on population health and the economy.